Open Access

Case report: maternal mosaicism resulting in inheritance of a novel GATA6 mutation causing pancreatic agenesis and neonatal diabetes mellitus

  • Daphne Yau1,
  • Elisa De Franco2,
  • Sarah E. Flanagan2,
  • Sian Ellard2,
  • Miriam Blumenkrantz3 and
  • John J. Mitchell1Email author
Diagnostic Pathology201712:1

https://doi.org/10.1186/s13000-016-0592-1

Received: 1 September 2016

Accepted: 8 December 2016

Published: 3 January 2017

Abstract

Background

Haploinsufficiency of the GATA6 transcription factor gene was recently found to be the most common cause of pancreatic agenesis, a rare cause of neonatal diabetes mellitus. Although most cases are de novo, we describe three siblings with inherited GATA6 haploinsufficiency and the rare finding of parental mosaicism.

Case Presentation

The proband was born at term with severe intrauterine growth restriction, the first child of non-consanguineous parents. Diabetes occurred on day of life 1 with pancreatic exocrine insufficiency noted at several months of age. Pancreatic agenesis with absent gallbladder was confirmed when he underwent congenital diaphragmatic hernia and intestinal malrotation repair. A patent ductus arteriosus and pulmonary stenosis were repaired in infancy. Neurocognitive development has been normal. A second pregnancy was terminated due to tetralogy of Fallot and pulmonary hypoplasia secondary to congenital diaphragmatic hernia. The fetus also demonstrated severe pancreatic hypoplasia, gallbladder agenesis and intestinal rotation abnormalities. Despite severe hypoplasia, the pancreas demonstrated normal islet histology. Another sibling was found to have multiple cardiac abnormalities, requiring procedural intervention. Given the proband’s spectrum of congenital anomalies, Sanger sequencing of the GATA6 gene was performed, revealing a novel heterozygous c.635_660del frameshift mutation (p.Pro212fs). The mutation is predicted to be pathogenic, resulting in inclusion of a premature stop codon and likely degradation of the gene transcript by nonsense-mediated decay. The abortus and the sibling with the cardiac defect were both found to have the mutation, while the father and remaining sibling were negative. The mother, who is healthy with no evidence of diabetes or cardiac disease, is mosaic for the mutation at a level of 11% in her peripheral leukocytes by next-generation sequencing.

Conclusion

We highlight a rare mechanism of pancreatic agenesis, this being only the second report of parental mosaicism for a GATA6 mutation and one of a handful of inherited cases. We also further define the phenotypic variability of GATA6 haploinsufficiency, even in individuals carrying the same mutation. Mutations in GATA6 should be strongly considered in cases of diabetes due to pancreatic hypoplasia or agenesis, and potentially affected family members should be tested regardless of phenotype.

Keywords

GATA6 Haploinsufficiency Mosaicism Pancreas abnormalities Neonatal diabetes mellitus

Background

Although type 1 diabetes mellitus accounts for the vast majority of pediatric diabetes, monogenic forms account for up to 4% of cases [1, 2]. The latter are due to single gene defects affecting pancreatic β-cell function, development or survival and include neonatal diabetes mellitus (NDM). NDM is defined as diabetes occurring in the first six months of life and occurs with an estimated frequency of approximately 1:100 000 live births [25]. Both transient and permanent forms of NDM exist (Table 1). Although clinically indistinguishable from each other at presentation, most transient cases resolve at a median age of 12 weeks but relapse in 50–60% [6, 7]. Different genetic loci and genes are associated with transient versus permanent NDM. Methylation abnormalities at chromosome 6q24 account for two thirds of transient cases, while in permanent NDM, activating mutations in ABCC8 and KCNJ11 are the most common genetic defects in outbred populations and EIF2AK3 is the most frequent in consanguineous groups [3, 7]. KCNJ11 and ABCC8 encode the KIR6.2 and SUR1 subunits of the KATP channel, respectively, which links glucose metabolism to insulin secretion. EIF2AK3 encodes a kinase involved in regulating the endoplasmic reticulum stress response to misfolded proteins [8, 9]. Although the mechanism causing diabetes is unclear, defects in EIF2AK3 may cause ER stress in the β-cell from misfolded proteins due to the high demand for insulin secretion, eventually leading to β-cell apoptosis. Alternatively, diabetes may be linked to reduced β-cell proliferation with abnormal insulin trafficking and secretion, as observed in EIF2AK3 knockout mice [9].
Table 1

Key genes associated with neonatal diabetes mellitus

Gene

Location

Inheritance

Clinical features

PLAGL1, HYMAI

6q24

Variable (imprinting)

Transient NDM

 

± Macroglossia, ± Umbilical Hernia, ± Other features if part of generalized hypomethylation syndrome

KCNJ11

11p15.1

De novo, Dominant or Recessive

Permanent or Transient NDM, ± Developmental delay, epilepsy, neonatal diabetes (DEND) syndrome

ABCC8

11p15.1

De novo, Dominant or Recessive

Transient or Permanent NDM, ± DEND syndrome

EIF2AK3

6q22.1

Recessive

Wolcott-Rallison Syndrome:

Permanent NDM

Short stature

Bone dysplasia

Hepatic dysfunction

INS

11p15.5

Recessive

Isolated permanent or transient NDM

GCK

7p15-p13

Recessive

Isolated permanent NDM

The most common genes associated with neonatal diabetes mellitus are described with key clinical features and mode of inheritance. Adapted from [2]. Genes associated with abnormal pancreas development are described in Table 2

Permanent NDM can also result from pancreatic agenesis or hypoplasia, which has been linked to mutations in transcription factors important for pancreatic and β-cell development. The most common of these is GATA6 [10]. Other causes include mutations in PDX1 and the PTF1A enhancer causing isolated abnormal pancreas development, while mutations in PTF1A, RFX6, HNF1B and GATA4 are associated with both pancreatic and extra-pancreatic abnormalities (Table 2) [1116]. GATA6 is one of a family of evolutionarily conserved transcription factors recognizing the A/T-GATA-A/G consensus sequence, with key roles in the development and differentiation of multiple cell lineages and tissues [17, 18]. Heterozygous inactivating mutations in GATA6 were identified through a whole exome sequencing strategy in 15/27 (56%) individuals with pancreatic agenesis, defined as NDM requiring insulin treatment and exocrine pancreatic insufficiency requiring enzyme replacement. This is a syndromic form of NDM associated with extra-pancreatic features including cardiac, hepatobiliary, gastrointestinal, neurocognitive and other endocrine involvement. Since its initial discovery, the phenotypic spectrum of GATA6 haploinsufficiency in humans has proven to be more diverse than initially appreciated, and although the initial cases were de novo, several instances of inherited GATA6 mutations have now been described [1921]. This report describes three siblings with inherited GATA6 haploinsufficiency and the rare finding of parental mosaicism.
Table 2

Genes associated with neonatal diabetes mellitus and abnormal pancreas development

Gene

Location

Inheritance

Clinical features

Reference

PDX1

13q12.1

Recessive

IUGR, Pancreatic agenesis, Permanent NDM, PI

[11]

PTF1A enhancer

10p12.2

Recessive

IUGR, Pancreatic agenesis, Permanent NDM, PI

[12]

PTF1A

10p12.2

Recessive

IUGR, Pancreatic agenesis, Permanent NDM, variable PI, Cerebellar hypoplasia/aplasia

[13]

RFX6

6q22.1

Recessive

IUGR, Annular/hypoplastic pancreas, Permanent NDM, Chronic diarrhea, Biliary and intestinal abnormalities

[14, 3235]

HNF1B

17q21.3

Dominant

IUGR, Pancreas hypoplasia, Renal cysts

[15]

GATA4

8p23.1

Dominant

IUGR, Pancreatic hypoplasia/agenesis, Congenital heart defects, Developmental delay

[16]

Genes in addition to GATA6 associated with both isolated diabetes and extra-pancreatic features are described with key clinical features and mode of inheritance

Case presentation

The proband was born at 37 weeks gestation after a pregnancy complicated by severe intrauterine growth restriction, reflected in the birth weight of 1.74 kg (<3rd percentile, −4 standard deviations). He was the first child of non-consanguineous parents of French Canadian background. Hyperglycemia occurred within the first 12 h of life and neonatal diabetes mellitus was diagnosed. An initial ultrasound visualized only the head of the pancreas, suggesting pancreatic hypoplasia. He was placed on subcutaneous insulin therapy with adequate glycemic control. Moderate valvular pulmonary stenosis and a patent ductus arteriosus (PDA) were also diagnosed and valvuloplasty was performed in the neonatal period.

At several months of age, recurrent episodes of hypoglycemia with decreasing insulin requirements began to occur. He was diagnosed with pancreatic exocrine insufficiency (PI) based on the recurrent hypoglycemia, poor weight gain and low stool fecal elastase, leading to initiation of pancreatic enzyme replacement. At 8 months of age, he was readmitted for severe failure to thrive and hypoglycemia secondary to inadequately treated PI, heart failure from the persistent PDA and a previously undiagnosed congenital diaphragmatic hernia. Intestinal malrotation was also noted. His medical management was optimized and he underwent repair of the PDA, diaphragmatic hernia and intestinal malrotation. At the time of surgery, no pancreatic tissue or gallbladder could be identified, demonstrating both pancreatic and gallbladder agenesis.

Despite improvement in his nutritional and overall health status, he continued to have episodes of early morning hypoglycemia, presumably due to deficient glucagon secretion. This was managed with feeds of uncooked cornstarch to provide a source of slowly-released glucose while on insulin injections and, when transitioned to pump therapy, with low basal insulin rates. Control of both the diabetes and exocrine insufficiency have been adequate with no evidence of malabsorption. There has been no clinical evidence of other endocrine dysfunction and thyroid function testing has been normal. He has also demonstrated appropriate neurocognitive development as of 9 years of age. Previous testing of the PDX1 gene, a recognized cause of pancreatic agenesis (Table 2) as well as broader genetic analysis through the 1,000,000 Single Nucleotide Polymorphism project were unrevealing.

A second pregnancy was terminated at 20 weeks due to complex congenital heart disease. Examination of the abortus revealed a male fetus with tetralogy of Fallot, congenital diaphragmatic hernia, severe pancreatic hypoplasia, gallbladder agenesis and intestinal non-rotation (Fig. 1, individual IIB). Subsequently, two male infants were born. The youngest child was found to have a PDA requiring procedural intervention, left pulmonary artery stenosis, and moderate atrial septal defect (Fig. 1, individual IID). Neither the remaining sibling nor either parent have any clinical evidence of diabetes, pancreatic exocrine insufficiency or cardiac disease.
Fig. 1

Family Pedigree. The proband (II-A) and abortus (II-B) have multiple congenital anomalies including severe pancreatic agenesis/hypoplasia, while one sibling (II-D), also heterozygous for the same mutation, has isolated congenital cardiac anomalies including a PDA, left pulmonary artery stenosis, moderate atrial septal defect. The father and remaining sibling are negative for the mutation. The genotypes are provided below each symbol, N denotes the wildtype allele

Methods

GATA6 sequencing

Genomic DNA was extracted from peripheral leukocytes using standard procedures. Exons 2–7 and the exon/intron boundaries of the GATA6 gene were analyzed by Sanger sequencing as described previously. Exon 1 is a non-coding exon and was not sequenced [10]. Sequencing reactions were run on an ABI3730 capillary machine (Applied Biosystems, Warrington, U.K.) and analyzed using Mutation Surveyor v4.0.6 (SoftGenetics, State College, PA) (GATA6 nucleotide reference NM_005257.3). Allele frequency was quantified by next-generation sequencing as previously described [22].

Histology

Immunohistochemistry and staining for hematoxylin, phloxine, saffron were performed using standard procedures on slides of pancreatic tissue obtained at autopsy from the abortus (Fig. 1, individual IIB). For the immunohistochemistry, antibodies were used to detect insulin, glucagon and somatostatin.

Results

Given the similarity between the proband’s spectrum of congenital anomalies and the clinical phenotype of GATA6 mutations, Sanger sequencing of exons 2–7 of the GATA6 gene was performed in peripheral leukocytes. A novel c.635_660del frameshift mutation (p.Pro212fs) was identified in the proband. The mutation is located in exon 2, within the transcriptional activation domain, and is predicted to result in inclusion of a premature stop codon and likely degradation of the gene transcript by nonsense-mediated decay (Fig. 2). The mother, the abortus and the sibling with the congenital heart defect were also found to carry the mutation (Fig. 1). Notably, the mother, who has no clinical evidence of diabetes, including gestational diabetes or cardiac disease, was found to be mosaic for the mutation (Fig. 1, individual IA). This was confirmed and quantified by next-generation sequencing, revealing 11% mosaicism in peripheral blood. The father and the remaining sibling’s testing were negative.
Fig. 2

Genomic and protein positions of the novel GATA6 mutation. a Exons 2 to 7 with the location of the novel deletion described are shown. b The frameshift resulting from the deletion is shown with its location in the transcriptional activation domain. The numbers refer to the amino acid position of the latter domain and the DNA-binding zinc fingers (ZnF)

Histological analysis of the pancreas from the abortus (Fig. 1, individual IIB) demonstrated well-formed islets despite severe pancreatic hypoplasia (Fig. 3). The majority of islet cells stained positive for insulin and were surrounded by smaller populations of glucagon and somatostatin positive cells, demonstrating normal islet morphology.
Fig. 3

Islet morphology is preserved with appropriate distribution of insulin- and glucagon-positive cells despite severe pancreas hypoplasia. Pancreas sections from individual II-B in Fig. 1 were stained using haematoxylin, phloxine and saffron staining (a), and immunohistochemistry for insulin, glucagon and somatostatin (b to d). Islets were identified (a) demonstrating normal morphology with central insulin (b), peripheral glucagon (c) and somatostatin staining (d). All images were photographed at 200× magnification

Discussion

We describe three siblings heterozygous for the same GATA6 mutation inherited via parental mosaicism, yet with widely different manifestations, further defining the clinical phenotype associated with this rare disease. Since the initial report of heterozygous GATA6 mutations as the most common cause of pancreatic agenesis or hypoplasia, a much greater degree of phenotypic variability has been recognized for both pancreatic and extra-pancreatic features [10, 19]. Diabetes mellitus is the most common pancreatic feature in 98% of cases (Table 3). Although the majority of cases present with NDM, in others diabetes develops later in life or has yet to occur by adulthood. Similarly, although clinical PI has been reported in 81% of cases, subclinical PI and normal exocrine function have also been described (Table 3) [10, 19, 23]. Of the extra-pancreatic features, cardiac defects are the most common, in 88% of cases, although gastrointestinal, hepatobiliary, neurodevelopmental and other endocrine involvement have also been reported (Table 3) [10, 1921, 2329]. The family described here illustrates this clinical variability. The proband has NDM and PI, with significant cardiothoracic, gastrointestinal and biliary involvement. A similar phenotype was seen in the second affected sibling whereas in contrast, the third sibling has isolated cardiac involvement. Thus, GATA6 haploinsufficiency needs to be strongly considered as a potential cause in cases of diabetes secondary to abnormal pancreas development and, if confirmed, a thorough, multi-system assessment, particularly cardiac, should be performed to evaluate for other abnormalities. Consideration should also be given to screening for glycemic abnormalities in those whom diabetes has not yet developed.
Table 3

Phenotypic spectrum associated with GATA6 haploinsufficiency

Clinical features

Spectrum and severity

Patients with GATA6 mutation, N = 41 (%)

Pancreatic Features

 Diabetes Mellitus

Neonatal/adult-onset

Total 40/41 (98), NDM 33/41 (81)a, Child-onset 4/41 (10)b,

Adult-onset 3/41 (7)

 Exocrine Insufficiency

Clinical/subclinicald

Total 33/37 (89)c, Clinical 30/37 (81)

Extra-Pancreatic Features

 Cardiac

Isolated septal defect/multiple complex defects

36/41 (88)

 Hepatobiliary

Gallbladder atresia, biliary atresia

13/41 (32)

 Gastrointestinal

Umbilical hernia, diaphragmatic hernia, intestinal malrotation

8/41 (20)

 Other Endocrine

Hypothyroidism, pituitary agenesis

7/41 (17)

 Neurocognitive

Developmentally appropriate/mild learning difficulties/severe developmental delay

13/41 (32)

 Genitourinary

Bicornuate uterus, hydronephrosis, hydroureter

2/41 (5)

Summary of the pancreatic and extra-pancreatic features of the published cases to date, demonstrating the variability of the phenotype [10, 1921, 2329]. aNDM group includes one case of transient NDM, bchildhood-onset group includes one case of impaired glucose tolerance in adolescence, cfour cases were excluded as no information on exocrine insufficiency was provided, dsubclinical was defined as low fecal elastase or positive fecal fat in the absence of clinical symptoms or need for pancreatic enzyme replacement

Although most cases of GATA6 mutations are de novo, several cases of dominant inheritance have been reported [10, 19]. The family described here is notable for being amongst these inherited cases and moreover, is only the second report of parental mosaicism [19]. In the previous report, the parent was known to have a congenital heart defect, whereas in our case the mother has no known cardiac abnormalities or pancreatic phenotype. Presumably differing levels of tissue mosaicism is key. Since three out of four offspring inherited the mutation, the level of mosaicism is likely significantly higher in the germline compared to other tissues in our case given the absence of other system involvement and almost certainly higher than the 11% detected in peripheral blood. Accordingly, testing of parents and other potentially affected family members should be performed, even in individuals without an obvious clinical phenotype.

The mechanism underlying the variable expressivity of GATA6 haploinsufficiency remains unclear with no obvious genotype-phenotype relationship [19]. Histologically, grossly preserved islet morphology was observed, which contrasts with murine models demonstrating abnormal morphogenesis with failure of progenitor cells to differentiate into endocrine and exocrine lineages (Fig. 3). However, humans appear to have greater sensitivity to GATA6 gene dosage as both Gata4 alleles in addition to at least one Gata6 allele must be inactivated in mice to cause pancreatic abnormalities [30, 31]. Although not explored in this report, at a molecular level, there are several potential mechanisms. In vitro studies have shown that missense mutations affecting highly conserved zinc finger residues result in failure to bind target promoters in luciferase reporter promoter assays [10, 19, 27]. Given the location of the novel frameshift mutation described here in the transactivation domain, there could be an impact on downstream genetic targets through altered binding of co-regulatory factors. However, the most likely explanation is that the introduction of a premature termination codon results in a reduction in GATA6 mRNA transcript levels through nonsense-mediated decay, as previously described [26]. Variable efficiency of this decay in different tissues could contribute to the phenotypic variability. Modifier genes, epigenetic mechanisms and environmental factors represent other potential mechanisms that could also contribute to the variability associated with GATA6 heterozygous mutations.

Conclusions

Heterozygous mutations in the GATA6 transcription factor gene are the most common cause of neonatal diabetes due to pancreatic agenesis. We describe three siblings heterozygous for the same GATA6 mutation inherited via parental mosaicism, a rare occurrence. Their markedly different manifestations illustrate both the importance of GATA6 for pancreas development as well as the phenotypic variability of GATA6 haploinsufficiency. Elucidating the mechanisms underlying the phenotype and its variability will improve our understanding of pancreas development and may provide insights into the mechanisms underlying other forms of abnormal pancreas development and neonatal diabetes.

Abbreviations

IUGR: 

intrauterine growth restriction

NDM: 

neonatal diabetes mellitus

PDA: 

patent ductus arteriosus

PI: 

pancreatic exocrine insufficiency

Declarations

Acknowledgments

The authors thank the family who participated in this study. We also thank A. Cuellar for his technical assistance regarding the immunohistochemistry.

Funding

JJM receives support from the Dr. Eleanor Mackenzie Harpur Pediatric Endowment Fund. The genetic testing in this report was funded by the Wellcome Trust via a Senior Investigator Award to SE. EDF is a Naomi Berrie Fellow in Diabetes Research. SEF has a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number 105636/Z/14/Z).

Availability of data and materials

The anonymized data analyzed during the current study is available from the corresponding author on reasonable request. Primer sequences used for GATA6 sequencing are available in reference 10 and its supplementary information files.

Authors’ contributions

JJM conceived of the study. GATA6 testing of the proband and family was coordinated by JJM and DY. SE, EDF and SF carried out the genetic analysis. MB performed and oversaw the histological analysis. DY wrote and JJM revised the manuscript. All authors read and approved the final manuscript.

Authors’ information

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Written informed consent for publication of their clinical details and/or clinical images was obtained from the parents of the patients. Copies of the consent forms are available for review by the Editor of this journal.

Ethics approval and consent to participate

The need for ethics approval from the institutional REB was waived as per provincial ethics and legal requirements. Consent was obtained as outlined above.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of Pediatric Endocrinology Montreal Children’s Hospital, McGill University Health Centre
(2)
Institute of Biomedical and Clinical Science, University of Exeter Medical School
(3)
Department of Pathology Montreal Children’s Hospital, McGill University Health Centre

References

  1. Craig ME, Jefferies C, Dabelea D, Balde N, Seth A, Donaghue KC. Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2014;15 Suppl 20:4–17.View ArticlePubMedGoogle Scholar
  2. Rubio-Cabezas O, Hattersley AT, Njølstad PR, Mlynarski W, Ellard S, White N, Chi DV, Craig ME. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2014;15 Suppl 20:47–64.View ArticlePubMedGoogle Scholar
  3. De Franco E, Flanagan SE, Houghton JA, Lango Allen H, Mackay DJ, Temple IK, Ellard S, Hattersley AT. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet. 2015;386:957–63.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Grulich-Henn J, Wagner V, Thon A, Schober E, Marg W, Kapellen TM, Haberland H, Raile K, Ellard S, Flanagan SE, et al. Entities and frequency of neonatal diabetes: data from the diabetes documentation and quality management system (DPV). Diabet Med. 2010;27:709–12.View ArticlePubMedGoogle Scholar
  5. Iafusco D, Massa O, Pasquino B, Colombo C, Iughetti L, Bizzarri C, Mammi C, Lo Presti D, Suprani T, Schiaffini R, et al. Minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births. Acta Diabetol. 2012;49:405–8.View ArticlePubMedGoogle Scholar
  6. Shield JP, Temple IK, Sabin M, Mackay D, Robinson DO, Betts PR, Carson DJ, Cave H, Chevenne D, Polak M. An assessment of pancreatic endocrine function and insulin sensitivity in patients with transient neonatal diabetes in remission. Arch Dis Child Fetal Neonatal Ed. 2004;89:F341–3.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Temple IK, Gardner RJ, Mackay DJ, Barber JC, Robinson DO, Shield JP. Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diabetes. 2000;49:1359–66.View ArticlePubMedGoogle Scholar
  8. Karges B, Meissner T, Icks A, Kapellen T, Holl RW. Management of diabetes mellitus in infants. Nat Rev Endocrinol. 2012;8:201–11.View ArticleGoogle Scholar
  9. Julier C, Nicolino M. Wolcott-rallison syndrome. Orphanet J Rare Dis. 2010;5:29.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Lango Allen H, Flanagan SE, Shaw-Smith C, De Franco E, Akerman I, Caswell R, nternational Pancreatic Agenesis Consortium, Ferrer J, Hattersley AT, Ellard S. GATA6 haploinsufficiency causes pancreatic agenesis in humans. Nat Genet. 2011;44:20–2.View ArticlePubMedGoogle Scholar
  11. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet. 1997;15:106–10.View ArticlePubMedGoogle Scholar
  12. Weedon MN, Cebola I, Patch AM, Flanagan SE, De Franco E, Caswell R, Rodriguez-Segui SA, Shaw-Smith C, Cho CH, Lango Allen H, et al. Recessive mutations in a distal PTF1A enhancer cause isolated pancreatic agenesis. Nat Genet. 2014;46:61–4.View ArticlePubMedGoogle Scholar
  13. Sellick GS, Barker KT, Stolte-Dijkstra I, Fleischmann C, Coleman RJ, Garrett C, Gloyn AL, Edghill EL, Hattersley AT, Wellauer PK, et al. Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet. 2004;36:1301–5.View ArticlePubMedGoogle Scholar
  14. Concepcion JP, Reh CS, Daniels M, Liu X, Paz VP, Ye H, Highland HM, Hanis CL, Greeley SA. Neonatal diabetes, gallbladder agenesis, duodenal atresia, and intestinal malrotation caused by a novel homozygous mutation in RFX6. Pediatr Diabetes. 2014;15:67–72.View ArticlePubMedGoogle Scholar
  15. Yorifuji T, Kurokawa K, Mamada M, Imai T, Kawai M, Nishi Y, Shishido S, Hasegawa Y, Nakahata T. Neonatal diabetes mellitus and neonatal polycystic, dysplastic kidneys: Phenotypically discordant recurrence of a mutation in the hepatocyte nuclear factor-1beta gene due to germline mosaicism. J Clin Endocrinol Metab. 2004;89:2905–8.View ArticlePubMedGoogle Scholar
  16. Shaw-Smith C, De Franco E, Lango Allen H, Batlle M, Flanagan SE, Borowiec M, Taplin CE, van Alfen-van der Velden J, Cruz-Rojo J, Perez de Nanclares G, et al. GATA4 mutations are a cause of neonatal and childhood-onset diabetes. Diabetes. 2014;63:2888–94.View ArticlePubMedGoogle Scholar
  17. Viger RS, Guittot SM, Anttonen M, Wilson DB, Heikinheimo M. Role of the GATA family of transcription factors in endocrine development, function, and disease. Mol Endocrinol. 2008;22:781–98.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Minami K. GATA transcription factors: New key regulators in pancreas organogenesis. J Diab Investig. 2013;4:426–7.View ArticleGoogle Scholar
  19. De Franco E, Shaw-Smith C, Flanagan SE, Shepherd MH, International NDM Consortium, Hattersley AT, Ellard S. GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency. Diabetes. 2013;62:993–7.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Bonnefond A, Sand O, Guerin B, Durand E, De Graeve F, Huyvaert M, Rachdi L, Kerr-Conte J, Pattou F, Vaxillaire M, et al. GATA6 inactivating mutations are associated with heart defects and, inconsistently, with pancreatic agenesis and diabetes. Diabetologia. 2012;55:2845–7.View ArticlePubMedGoogle Scholar
  21. Yorifuji T, Kawakita R, Hosokawa Y, Fujimaru R, Yamaguchi E, Tamagawa N. Dominantly inherited diabetes mellitus caused by GATA6 haploinsufficiency: variable intrafamilial presentation. J Med Genet. 2012;49:642–3.View ArticlePubMedGoogle Scholar
  22. Ellard S, Lango Allen H, De Franco E, et al. Improved genetic testing for monogenic diabetes using targeted next-generation sequencing. Diabetologia. 2013;56:1958–63.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Catli G, Abaci A, Flanagan SE, De Franco E, Ellard S, Hattersley A, Guleryuz H, Bober E. A novel GATA6 mutation leading to congenital heart defects and permanent neonatal diabetes: a case report. Diab Metab. 2013;39:370–4.View ArticleGoogle Scholar
  24. Gong M, Simaite D, Kuhnen P, Heldmann M, Spagnoli F, Blankenstein O, Hubner N, Hussain K, Raile K. Two novel GATA6 mutations cause childhood-onset diabetes mellitus, pancreas malformation and congenital heart disease. Horm Res Paediatr. 2013;79:250–6.View ArticlePubMedGoogle Scholar
  25. Eifes S, Chudasama KK, Molnes J, Wagner K, Hoang T, Schierloh U, Rocour-Brumioul D, Johansson S, Njolstad PR, de Beaufort C. A novel GATA6 mutation in a child with congenital heart malformation and neonatal diabetes. Clin Case Rep. 2013;1:86–90.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Suzuki S, Nakao A, Sarhat AR, Furuya A, Matsuo K, Tanahashi Y, Kajino H, Azuma H. A case of pancreatic agenesis and congenital heart defects with a novel GATA6 nonsense mutation: evidence of haploinsufficiency due to nonsense-mediated mRNA decay. Am J Med Genet A. 2014;164A:476–9.View ArticlePubMedGoogle Scholar
  27. Chao CS, McKnight KD, Cox KL, Chang AL, Kim SK, Feldman BJ. Novel GATA6 mutations in patients with pancreatic agenesis and congenital heart malformations. PLoS One. 2015;10:e0118449.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Tuhan H, Catli G, Anik A, Ozmen D, Turkmen MA, Bober E, Abaci A. Neonatal diabetes mellitus due to a novel mutation in the GATA6 gene accompanying renal dysfunction: a case report. Am J Med Genet A. 2015;167A:925–7.View ArticlePubMedGoogle Scholar
  29. Stanescu DE, Hughes N, Patel P, De Leon DD. A novel mutation in GATA6 causes pancreatic agenesis. Pediatr Diabetes. 2015;16:67–70.View ArticlePubMedGoogle Scholar
  30. Carrasco M, Delgado I, Soria B, Martin F, Rojas A. GATA4 and GATA6 control mouse pancreas organogenesis. J Clin Invest. 2012;122:3504–15.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Xuan S, Borok MJ, Decker KJ, Battle MA, Duncan SA, Hale MA, Macdonald RJ, Sussel L. Pancreas-specific deletion of mouse Gata4 and Gata6 causes pancreatic agenesis. J Clin Invest. 2012;122:3516–28.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Chappell L, Gorman S, Campbell F, Ellard S, Rice G, Dobbie A, Crow Y. A further example of a distinctive autosomal recessive syndrome comprising neonatal diabetes mellitus, intestinal atresias and gall bladder agenesis. Am J Med Genet A. 2008;146A:1713–7.View ArticlePubMedGoogle Scholar
  33. Mitchell J, Punthakee Z, Lo B, Bernard C, Chong K, Newman C, Cartier L, Desilets V, Cutz E, Hansen IL, et al. Neonatal diabetes, with hypoplastic pancreas, intestinal atresia and gall bladder hypoplasia: search for the aetiology of a new autosomal recessive syndrome. Diabetologia. 2004;47:2160–7.View ArticlePubMedGoogle Scholar
  34. Smith SB, Qu HQ, Taleb N, Kishimoto NY, Scheel DW, Lu Y, Patch AM, Grabs R, Wang J, Lynn FC, et al. Rfx6 directs islet formation and insulin production in mice and humans. Nature. 2010;463:775–80.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Spiegel R, Dobbie A, Hartman C, de Vries L, Ellard S, Shalev SA. Clinical characterization of a newly described neonatal diabetes syndrome caused by RFX6 mutations. Am J Med Genet A. 2011;155A:2821–5.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement